Market share of major diabetes drugs in China H1 2022

In the first half of 2022, Xiaoke pill held a share of more than 23 percent in the public healthcare market in China, ranked first among diabetes drugs. Meanwhile, Yiling Pharmaceutical's Jinlida granule remained an important diabetes drug.

在2022年上半年，小克药片在中国公立医疗市场所占份额超过23%，在糖尿病药物中位居首位。与此同时，以岭药业的金铃颗粒仍为重要的糖尿病用药。